🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. BMS-641988 (AR#2)

    Bristol-Myers Squibb

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  2. BMS-906024

    Bristol-Myers Squibb

    Cancer

    phase 1 small molecule completed

    1 trial

  3. BMS-986148

    Bristol-Myers Squibb

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  4. BMS-986202

    Bristol-Myers Squibb

    Psoriasis

    phase 1 small molecule completed

    1 trial

  5. BMS-986500

    Bristol-Myers Squibb

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  6. BXCL501 80 Micrograms

    BioXcel Therapeutics

    Schizophrenia

    phase 1 small molecule active

    1 trial

  7. Bioequivalence of Cladribine 10 mg from two different products

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).

    phase 1 other active

    1 trial

  8. Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl

    Alphapharm Pty Ltd

    Bioequivalence trial in healthy volunteers

    phase 1 other active

    1 trial

  9. Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl

    Alphapharm Pty Ltd

    Bioequivalence trial in healthy volunteers

    phase 1 other active

    1 trial

  10. Boserolimab

    Merck KGaA, Darmstadt, Germany

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  11. Brentuximab Vedotin

    Takeda

    Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic

    phase 1 small molecule terminated

    1 trial

  12. CPX-351 (Cytarabine:Daunorubicin) Liposome Injection

    Jazz Pharmaceuticals Ireland Limited

    Hematologic Neoplasms

    phase 1 small molecule completed

    1 trial

  13. Camsirubicin

    Monopar Therapeutics

    Advanced Soft-tissue Sarcoma

    phase 1 small molecule terminated

    1 trial

  14. Cemsidomide

    C4 Therapeutics

    Multiple Myeloma (MM)

    phase 1 small molecule active

    1 trial

  15. DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis, Myasthenia Gravis

    phase 1 small molecule active

    1 trial

  16. ETC-159

    BRIGHT MINDS BIOSCIENCES INC.

    With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  17. Effect of Renal Impairment on Enpatoran Pharmacokinetics

    Merck Sharp and Dohme

    Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).

    phase 1 other active

    1 trial

  18. Entinostat

    Syndax Pharmaceuticals

    Neoplasms

    phase 1 small molecule completed

    2 trials

  19. First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients

    Lacuna Pharma Pty Ltd

    Olmsted syndrome

    phase 1 other active

    1 trial

  20. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  21. G207

    BRIGHT MINDS BIOSCIENCES INC.

    Supratentorial Neoplasms, Malignant

    phase 1 mab completed

    1 trial

  22. GSK5533524

    GlaxoSmithKline

    Neoplasms

    phase 1 small molecule active

    1 trial

  23. GX15-070MS

    Teva Pharma GmbH

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  24. Gallium-68 citrate

    United Therapeutics Europe Ltd

    Prostatic Neoplasms

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources